Evidence map›Paper›PMID 37047372›Full record

ArticleInternational journal of molecular sciences2023

Generating Functional and Highly Proliferative Melanocytes Derived from Human Pluripotent Stem Cells: A Promising Tool for Biotherapeutic Approaches to Treat Skin Pigmentation Disorders.

Manoubia Saidani, Annabelle Darle, Margot Jarrige, Hélène Polveche, Lina El Kassar, Séverine Julié, Sandrine Bessou-Touya, Nathalie Holic, Gilles Lemaitre, Cécile Martinat and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Manoubia SaidaniCentre d'Etude des Cellules Souches, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, French Muscular Disease Association, 91100 Corbeil-Essonnes, France.
Annabelle DarleCentre d'Etude des Cellules Souches, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, French Muscular Disease Association, 91100 Corbeil-Essonnes, France.
Margot JarrigeCentre d'Etude des Cellules Souches, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, French Muscular Disease Association, 91100 Corbeil-Essonnes, France.
Hélène PolvecheCentre d'Etude des Cellules Souches, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, French Muscular Disease Association, 91100 Corbeil-Essonnes, France.ORCID 0000-0002-5601-3498
Lina El KassarCentre d'Etude des Cellules Souches, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, Cell Biology Platform, Research and Technological Innovation Team, 91100 Corbeil-Essonnes, France.
Séverine JuliéPharmacology Unit, Pierre Fabre Dermo-Cosmétique, 31100 Toulouse, France.
Sandrine Bessou-TouyaPharmacology Unit, Pierre Fabre Dermo-Cosmétique, 31100 Toulouse, France.ORCID 0000-0002-3693-8055
Nathalie HolicINSERM U861, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, 91100 Corbeil-Essonnes, France.
Gilles LemaitreU861, Evry Val d'Essonne/Paris-Saclay University, 91100 Corbeil-Essonnes, France.ORCID 0000-0002-0898-1582
Cécile MartinatINSERM U861, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, 91100 Corbeil-Essonnes, France.ORCID 0000-0002-5234-1064
Christine BaldeschiINSERM U861, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, 91100 Corbeil-Essonnes, France.ORCID 0000-0001-6624-0507
Jennifer AlloucheINSERM U861, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, 91100 Corbeil-Essonnes, France.ORCID 0000-0002-2379-0979
Institut des Cellules Souches pour le Traitement et l'Étude des Maladies Monogéniques · FRInserm · FRPierre Fabre (France) · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanocytes are essential for skin homeostasis and protection, and their loss or misfunction leads to a wide spectrum of diseases. Cell therapy utilizing autologous melanocytes has been used for years as an adjunct treatment for hypopigmentary disorders such as vitiligo. However, these approaches are hindered by the poor proliferative capacity of melanocytes obtained from skin biopsies. Recent advances in the field of human pluripotent stem cells have fueled the prospect of generating melanocytes. Here, we have developed a well-characterized method to produce a pure and homogenous population of functional and proliferative melanocytes. The genetic stability and potential transformation of melanocytes from pluripotent stem cells have been evaluated over time during the in vitro culture process. Thanks to transcriptomic analysis, the molecular signatures all along the differentiation protocol have been characterized, providing a solid basis for standardizing the protocol. Altogether, our results promise meaningful, broadly applicable, and longer-lasting advances for pigmentation disorders and open perspectives for innovative biotherapies for pigment disorders.

Indexed as

Pigmentation DisordersPluripotent Stem CellsVitiligoHumansMelanocytesSkinSkin Pigmentationhuman pluripotent stem cellpigmentation-related skin disordersskin regeneration

Identifiers

PMID37047372
PMCPMC10094141
OpenAlexW4361286883

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.